Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Remimazolam plus remifentanil dose-finding for painless gastroscopy in elderly patients
ChiCTR2500102113Phase 4Completed
- Sponsor
- The First Affiliated Hospital of Xi'an Medical University
- Start
- May 2025
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of remimazolam and remifentanil (3 arms), sponsored by The First Affiliated Hospital of Xi'an Medical University. Primary endpoints: half-effective dose and 95% effective dose. Started May 2025; status: completed.
02
Drugs
remimazolamremifentanil
Beyond the preview
Go deeper on ChiCTR2500102113.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500102113.